InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

South Korea: In a post hoc analysis of the randomized PULSAR trial, aflibercept 8 mg demonstrated noninferior visual outcomes ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

To help protect yourself and your family from getting seriously ill, you may want to learn about additional vaccine options ...

Risk factors for relapse after reinduction treatment with rituximab in patients with antineutrophil cytoplasmic ...

Negative symptoms of schizophrenia affect motivation, emotion, and daily life. Learn the signs, why they’re often missed, and ...

Maintenance therapy with subcutaneous infliximab was more effective than placebo regardless of disease location or segment ...

Traditional rule-based systems, once sufficient for detecting simple patterns of fraud, have been overwhelmed by the scale, ...

The season ahead will be shaped by fan-driven decisions – small, frequent, measurable interactions that build loyalty through agency.

Find out how higher dose aflibercept may reduce injection burden while preserving vision in retinal vasculopathy.

New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...